Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

1029362

registered interest
date	20/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Life Expectancy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of trends in life expectancy.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	204558
answer	answer is ministerial correction date of answer 11/01/2019 answer text <p>Public Health England (PHE) was commissioned by the Department in 2018 to review trends in life expectancy and mortality in England. PHE’s review was released on 11 December 2018 and is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/recent-trends-in-mortality-in-england-review-and-data-packs" target="_blank">https://www.gov.uk/government/publications/recent-trends-in-mortality-in-england-review-and-data-packs</a></p><p> </p><p>The review summarises the findings from the commission and suggests further work that could be undertaken, by PHE or others. It provides a review of official data to advance understanding of the trends in life expectancy and mortality in England, as well as more detail on specific population groups and specific causes of death, including insight into possible explanations for the trends observed.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/01/2019 12:10:18 answering member 4067 label Biography information for Steve Brine
tabling member	4471 label Biography information for Rachael Maskell

1029368

registered interest
date	20/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Labour Turnover
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent steps he has taken to improve the retention level of GPs within the NHS.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	204563
answer	answer is ministerial correction date of answer 09/01/2019 answer text <p>NHS England and Health Education England (HEE) are working together with the profession to increase the general practitioner (GP) workforce. This includes measures to boost recruitment, address the reasons why GPs are leaving the profession, and encourage GPs to return to practice.</p><p> </p><p>There is a broad offer available to support GPs to remain in the National Health Service including the GP Health Service, the GP Retention Scheme, and the GP Retention Fund.</p><p> </p><p>In May 2018, NHS England launched the £10 million GP Retention Fund, comprising of the Local Retention Fund (£7 million) and the Intensive Support Areas (£3 million) which will help GPs stay in the workforce by promoting new ways of working and offering additional support.</p><p> </p><p>Recognising that workload is one of the biggest issues impacting retention, NHS England is investing £30 million in the Releasing Time for Care Programme, which aims to help practices reduce their workload through spreading awareness of innovations and facilitating local programmes.</p><p> </p><p>Getting the skills mix right in general practice is also critical in addressing workload pressures as well as in delivering appropriate patient care. This will mean bigger teams of staff, providing a wider range of care options for patients and freeing up more time for GPs to focus on those with more complex needs. As of September 2018, there were over 3,700 more clinical staff, excluding GPs, working in general practice since 2015; consisting of over 600 more nurses and over 3,000 more other direct patient care.</p><p> </p><p>In addition to this work, the General Practice Partnership Review, an independent review into the partnership model to which practices work, will deliver its final report early this year. The independent review will consider key questions around workforce and workload and make a number of recommendations with the aim of ensuring general practice remains an excellent place to work.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2019 15:04:10 answering member 4067 label Biography information for Steve Brine
tabling member	4471 label Biography information for Rachael Maskell

1029369

registered interest
date	20/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Visual Impairment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle preventable blindness.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	204564
answer	answer is ministerial correction date of answer 09/01/2019 answer text <p>The Government takes the concerns around reported avoidable sight loss very seriously. Following the All Party Parliamentary Group on Eye Health and Visual Impairment’s ‘See the Light’ report, initial meetings have been held with key stakeholders to discuss the Department and NHS England’s response to the report’s recommendations and these discussions are ongoing.</p><p> </p><p>Two key initiatives, Getting it Right First Time being led by NHS Improvement and the Elective Care Transformation Programme being led by NHS England have considered, as part of their programmes, what can be done to ensure patients do not suffer unnecessary delays in follow-up care for ophthalmology.</p><p> </p><p>Action is also being taken to reduce sight loss caused by medical conditions. On diabetic retinopathy, a common complication of diabetes which can lead to sight loss, a diabetic retinopathy screening programme led by Public Health England offered screening to 2.4 million eligible people in 2015/16.</p><p> </p><p>Early detection is also key and free National Health Service sight tests are available to those at increased risk of eye disease or likely to be deterred from seeking private tests on grounds of cost.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2019 15:05:38 answering member 4067 label Biography information for Steve Brine
tabling member	4471 label Biography information for Rachael Maskell

1028525

registered interest
date	19/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Public Health: Waste Management
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the effects of the policies outlined in the Waste and Resources Strategy, published on 18 December 2018, on public health.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	203774
answer	answer is ministerial correction date of answer 09/01/2019 answer text <p>Public Health England has not made an assessment of the effects of the policies outlined in the Waste and Resources Strategy on public health.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2019 15:12:45 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

1028526

registered interest
date	19/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Incinerators: Health Hazards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 27 November 2018 to Question 193367, what evidence Public Health England has considered on the effects of dioxins released during incineration of municipal waste on human health.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	203775
answer	answer is ministerial correction date of answer 09/01/2019 answer text <p>Public Health England’s (PHE’s) position is that well run and regulated modern municipal waste incinerators (MWIs) are not a significant risk to public health. This view is based on detailed assessments of the effects of air pollutants on health and the fact that modern and well managed MWIs make only a very small contribution to local concentrations of air pollutants.</p><p> </p><p>This review included consideration of dioxins and explains that the emissions from incinerators should have a negligible impact on the level of dioxin exposure of the surrounding population either from direct inhalation or exposure from locally produced foodstuffs. Therefore the dioxin emissions from incinerators are unlikely to have any appreciable effect on health.</p><p> </p><p>When consulted, PHE provides an expert and independent opinion to the regulator (Environment Agency) on the potential impacts, including from dioxins, on human health of emissions arising from existing or proposed regulated facilities, such as MWIs.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2019 15:11:59 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

1028622

registered interest
date	19/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the NICE guidance, Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer, published in December 2018, what NHS England’s position is on that guidance.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	203875
answer	answer is ministerial correction date of answer 07/01/2019 answer text <p>NHS England is supportive of the updated National Institute for Health and Care Excellence guidance and is actively considering making available both of the two new tests that it recommends, alongside Oncotype Dx which is already available to patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/01/2019 13:34:47 answering member 4067 label Biography information for Steve Brine
tabling member	4056 label Biography information for Nic Dakin

1028635

registered interest
date	19/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 December 2018 to Question 201214 on Rare Diseases: Drugs, on how many occasions NICE has made a conditional recommendation for a rare disease treatment that do not qualify for conditional recommendation through the cancer drugs fund; and what criteria NICE uses to determine whether such treatments are eligible for conditional recommendations.
tabling member constituency	Bury North
tabling member printed	James Frith
uin	203975
answer	answer is ministerial correction date of answer 07/01/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is able to take into account the commercial terms offered by a manufacturer during a NICE appraisal through a mechanism known as a commercial access agreement. On two occasions NICE has issued optimised recommendations to make rare disease medicines routinely available for the appropriate group of National Health Service patients that are conditional on it being supplied in accordance with the terms of the commercial access arrangements. These were Sorafenib, for advanced hepatocellular carcinoma, and ibrutinib for relapsed or refractory mantle cell lymphoma.</p><p> </p><p>This is different from the process of a conditional recommendation for use within the Cancer Drugs Fund (CDF) for oncology drugs, where there is significant remaining clinical uncertainty which needs more investigation through data collection. In these cases funding is provided from the CDF for a time-limited period to allow patient access whilst this data is collected, before guidance is then reviewed again for routine commissioning.</p><p> </p><p>NICE does not have any particular criteria to determine whether treatments are eligible for conditional recommendations. However, the process guide for patient access schemes and commercial access agreements and the CDF can be found at the following link:</p><p><a href="https://www.nice.org.uk/process/pmg19/chapter/patient-access-schemes-commercial-access-agreements-and-flexible-pricing" target="_blank">https://www.nice.org.uk/process/pmg19/chapter/patient-access-schemes-commercial-access-agreements-and-flexible-pricing</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/01/2019 13:32:56 answering member 4067 label Biography information for Steve Brine
tabling member	4637 label Biography information for James Frith

1028650

registered interest
date	19/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tameside and Glossop Clinical Commissioning Group
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the (a) role and (b) responsibilities are of the Chief Executive of Tameside and Glossop NHS Clinical Commissioning Group.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	203819
answer	answer is ministerial correction date of answer 09/01/2019 answer text <p>The role of the Accountable Officer, which is equivalent to a Chief Executive, is summarised by the Tameside and Glossop Clinical Commissioning Group Constitution as:</p><p>“i. being responsible for ensuring that the clinical commissioning group fulfils its duties to exercise its functions effectively, efficiently, and economically thus ensuring improvement in the quality of services and in the health of the local population whilst maintaining value for money,</p><p>ii. at all times ensuring that the regularity and propriety of expenditure is discharged, and that arrangements are put in place to ensure that good practice (as identified through relevant national bodies and agencies) is embodied and that safeguarding of funds is ensured through effective financial and management systems,</p><p>iii. working closely with the Chair of the Governing Body, the Accountable Officer will ensure that proper constitutional, governance, and development arrangements are put in place to assure the members (through the Governing Body) of the organisation’s on-going capability and capacity to meet its duties and responsibilities. This will include arrangements for the on-going development of its members and staff.”</p><p> </p><p>The key responsibilities of the Accountable Officer are defined by NHS Tameside and Glossop CCG as:</p><p>&quot;i.T o contribute to developing the strategic direction of the GP Commissioning Consortium (GPCC), translating the strategic objectives of the Consortium into operational plans and managing their delivery.</p><p>ii. To lead the accreditation process for licencing of the Consortium, working with NHS North West and the Greater Manchester Cluster to ensure that accreditation criteria is met and that the Consortium is successful is successful in its application to become an authorised GPCC by April 2012/2013 and can be established as a NHS Consortium statutory body.</p><p>iii. To lead the development of the transition plan, developing organisational structures, systems and processes and ensuring that they are fit for purpose and working closely with the Greater Manchester Cluster in order to implement Quality, Innovation, Prevention and Productivity plans and reach consensus on shared services, risk management and commissioning approaches.</p><p>iv. To be responsible for ensuring wide engagement with senior stakeholders from the local health and social care economy, developing and maintaining existing partnership working and actively pursuing opportunities to partnerships within the community which will promote the health and wellbeing of the population.</p><p>v. To provide or procure comprehensive commissioning and support functions to support the Consortium, performance managing their delivery.”</p><p> </p><p>Further information can be found in the attached document.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2019 14:56:07 answering member 4067 label Biography information for Steve Brine attachment 1 file name SP AO TGCCG.PDF title PQ203819 attached document
tabling member	1506 label Biography information for Andrew Gwynne

1028653

registered interest
date	19/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Alcoholic Drinks: Minimum Unit Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effect of the introduction of minimum unit pricing for alcohol in Scotland on (a) the level of consumption of alcohol and (b) public health.
tabling member constituency	Southampton, Itchen
tabling member printed	Royston Smith
uin	203934
answer	answer is ministerial correction date of answer 09/01/2019 answer text <p>No assessment has been made of the effect of the introduction of minimum unit pricing of alcohol in Scotland. The introduction of minimum unit pricing in England remains under review.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2019 15:08:15 answering member 4067 label Biography information for Steve Brine
tabling member	4478 label Biography information for Royston Smith

1028683

registered interest
date	19/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Skin Cancer: Sunbeds
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the link between sunbed usage and diagnosis of melanomas; and if he will make a statement.
tabling member constituency	Chesterfield
tabling member printed	Toby Perkins
uin	203867
answer	answer is ministerial correction date of answer 09/01/2019 answer text <p>The International Agency for Research on Cancer has assessed ultraviolet radiation (UV) emitting tanning devices as “carcinogenic to humans” based on consistent evidence of a positive association between their use and incidence of melanoma.</p><p> </p><p>In the United Kingdom the Committee on Medical Aspects of Radiation in the Environment have published advice to the Government on the health effects and risks from UV sunbeds. Their report concluded that there is evidence to suggest an increased risk of skin cancer among those who use sunbeds before the age of 35. The ‘UV radiation exposure health risks from artificial tanning devices’ report is available to view at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/comare-13th-report" target="_blank">https://www.gov.uk/government/publications/comare-13th-report</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2019 15:09:33 answering member 4067 label Biography information for Steve Brine
tabling member	3952 label Biography information for Mr Toby Perkins